Govt Gives Nod To Several Firms Under PLI Scheme For Medical Devices

New Delhi : The government has approved applications from several medical devices manufacturers under the Production Linked Incentive (PLI) scheme for the promotion of domestic manufacturing, an official statement said.

The companies include Siemens Healthcare, Sahajanand Medical Technologies, Nipro India Corporation and Wipro GE Healthcare, the Ministry of Chemicals and Fertilizers said.

The setting up of these plants will lead to a total committed investment of 729.63 crore by the companies and employment generation for about 2,304 persons, it added.

“The commercial production is projected to commence from April 1, 2022 and the disbursal of production linked incentive by the Government over the five years period would be up to a maximum of 121 crore per applicant per target segment,” the statement said.

The setting up of these plants will make the country self-reliant to a large extent in the specified target segments in the medical devices sector, it added.

Applications were invited under four different target segments, including cancer care/radiotherapy medical devices, radiology and imaging and nuclear imaging devices, anaesthetics and cardio-respiratory medical devices, including catheters of cardio-respiratory category & renal care medical devices, and all implants including implantable electronic devices, the ministry said.

The Department of Pharmaceuticals had launched a PLI scheme for promotion of domestic manufacturing of medical devices to ensure a level playing field for the domestic manufacturers with a total financial outlay of 3,420 crore for the period 2020-21 to 2027-28, it added.

Related Posts

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

US appeals court sides with Sun Pharma in Lipitor antitrust case

US appeals court sides with Sun Pharma in Lipitor antitrust case

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad